Filing Details
- Accession Number:
- 0001209191-19-035777
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-06-10 16:14:29
- Reporting Period:
- 2019-06-06
- Accepted Time:
- 2019-06-10 16:14:29
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1293971 | Bluebird Bio Inc. | BLUE | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1578696 | David Davidson | C/O Bluebird Bio, Inc. 60 Binney Street Cambridge MA 02142 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-06-06 | 5,060 | $50.51 | 36,676 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-06-06 | 2,216 | $121.68 | 34,460 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-06-06 | 1,344 | $122.43 | 33,116 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-06-06 | 1,500 | $124.23 | 31,616 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2019-06-06 | 5,060 | $0.00 | 5,060 | $50.51 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 27,075 | 2026-03-01 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2019.
- The range in prices for the transaction reported on this line was $121.11 to $122.05. The average weighted price was $121.6806. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The range in prices for the transaction reported on this line was $122.145 to $122.85. The average weighted price was $122.4332. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The range in prices for the transaction reported on this line was $123.91 to $124.79. The average weighted price was $124.2294. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 4, 2017 and in 36 equal monthly installments thereafter.
Billionaire Hedge Funds
